Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07690826
PHASE2

A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.

Official title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Participants With Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

252

Start Date

2026-07

Completion Date

2027-07

Last Updated

2026-07-08

Healthy Volunteers

No

Interventions

DRUG

HRS-4729 Injection

HRS-4729 Injection; Dose 1

DRUG

HRS-4729 Injection

HRS-4729 Injection; Dose 2

DRUG

HRS-4729 Injection

HRS-4729 Injection; Dose 3

DRUG

HRS-4729 Injection;

HRS-4729 Injection; Dose 4

DRUG

HRS-4729 Injection;

HRS-4729 Injection; Dose 5

DRUG

HRS-4729 Injection;

HRS-4729 Injection; Dose 6

DRUG

HRS-4729 Injection Placebo

HRS-4729 Injection Placebo

Locations (1)

Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China